Hikma Pharmaceuticals USA, a subsidiary of UK-based Hikma Pharmaceuticals plc (LON:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY), announced on Saturday that it will invest USD1bn by 2030 to further expand its US manufacturing and R&D capabilities.

Hikma say that this new phase of investment, 'America Leans on Hikma: Quality Medicines Manufactured in the USA', will further expand its domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.

Hikma has operated in the United States since 1991 and has spent more than USD4bn over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines.

America Leans on Hikma represents the company's latest effort to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion is intended to help to strengthen Hikma's portfolio of more than 800 medicines and increase its US-based capacity.